Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United ...
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is an early-stage healthcare company developing and commercializing novel sublingual drug delivery systems aimed at improving how existing therapeutics are absorbed and used. The company’s core technology focuses on creating soluble, fast-acting formulations that can be delivered under the tongue, enabling quicker dissolution and ...Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is an early-stage healthcare company developing and commercializing novel sublingual drug delivery systems aimed at improving how existing therapeutics are absorbed and used. The company’s core technology focuses on creating soluble, fast-acting formulations that can be delivered under the tongue, enabling quicker dissolution and absorption compared with more traditional oral dosage forms.
Business and product focus centers on its flagship product candidate/designated product: Instaprin, an advanced sublingual aspirin formulation intended to support rapid onset for cardiovascular emergencies and also for general pain management. Beyond aspirin, Aspire Biopharma has described a diversified pipeline of sublingual/orally dissolving formulations, including a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. The company has also discussed extending its sublingual development efforts into additional therapeutic areas such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, along with exploration of caffeine-related products (including a single-dose sublingual pre-workout supplement).
From a product-development and service perspective, Aspire operates primarily as a technical/biopharmaceutical formulation developer—creating proprietary formulation approaches rather than operating a large-scale manufacturing and distribution network typical of mature pharma companies. As an emerging issuer, much of the work is expected to be oriented toward R&D, formulation refinement, regulatory progression, and commercialization planning for specific drug candidates. This also implies that the cost structure may be research- and development-heavy relative to near-term revenues.
Financially, the provided snapshot indicates the company is not generating positive profitability at present (negative margins and negative returns in the ttm set). With limited scale evidenced by the dataset showing 0 full-time employees, Aspire appears best characterized as a small, early-stage organization where key activities are likely concentrated around technical development, clinical/technical milestones, and partnership or licensing opportunities typical for companies advancing platform technologies.
Key people include CEO Kraig T. Higginson, who serves as the company’s top executive. Given the company’s positioning and described pipeline breadth, the strategic “wish list” for Aspire is generally consistent with advancing formulation technology into multiple therapeutic products—progressing candidates toward commercialization while leveraging its sublingual platform to differentiate time-to-effect and usability for patients and clinicians.
Overall, Aspire Biopharma’s value proposition rests on accelerating delivery and improving patient experience through sublingual formulations, starting with Instaprin and extending into a broader set of therapeutic and wellness applications.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$6202
—
+565.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-24.5M
-1768.9%
+31.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
-1.9%
—
+186.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-312016.9%
—
+86.6%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-394725.1%
—
+89.7%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-4.9M
-1756.6%
+30.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-79385.5%
—
+89.5%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-21.7%
+73.6%
-100.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.17x
+97.1%
+253.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
